Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supraglottic airway versus direct laryngoscopy for surfactant delivery in late preterm and term newborns with respiratory distress
ACTRN12619000995178Phase 3Recruiting
- Sponsor
- Women's and Children's Hospital
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Women's and Children's Hospital. Primary endpoint: Primary outcome: respiratory severity score. Started May 2020; status: recruiting.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on ACTRN12619000995178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000995178.